Skip to main content

Improved killing of HIV-infected cells using three neutralizing and non-neutralizing antibodies.

Publication ,  Journal Article
Tuyishime, M; Garrido, C; Jha, S; Moeser, M; Mielke, D; LaBranche, C; Montefiori, D; Haynes, BF; Joseph, S; Margolis, DM; Ferrari, G
Published in: J Clin Invest
October 1, 2020

The correlation of HIV-specific antibody-dependent cellular cytotoxicity (ADCC) responses with protection from and delayed progression of HIV-1 infection provides a rationale to leverage ADCC-mediating antibodies for treatment purposes. We evaluated ADCC mediated by different combinations of 2 to 6 neutralizing and non-neutralizing anti-HIV-1 Envelope (Env) mAbs, using concentrations ≤ 1 μg/mL, to identify combinations effective at targeting latent reservoir HIV-1 viruses from 10 individuals. We found that within 2 hours, combinations of 3 mAbs mediated more than 30% killing of HIV-infected primary CD4+ T cells in the presence of autologous NK cells, with the combination of A32 (C1C2), DH511.2K3 (MPER), and PGT121 (V3) mAbs being the most effective. Increasing the incubation of target and effector cells in the presence of mAb combinations from 2 to 24 hours resulted in increased specific killing of infected cells, even with neutralization-resistant viruses. The same combination eliminated reactivated latently HIV-1-infected cells in an ex vivo quantitative viral outgrowth assay. Therefore, administration of a combination of 3 mAbs should be considered in planning in vivo studies seeking to eliminate persistently HIV-1-infected cells.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Clin Invest

DOI

EISSN

1558-8238

Publication Date

October 1, 2020

Volume

130

Issue

10

Start / End Page

5157 / 5170

Location

United States

Related Subject Headings

  • Virus Latency
  • Neutralization Tests
  • Middle Aged
  • Male
  • Kinetics
  • Killer Cells, Natural
  • In Vitro Techniques
  • Immunotherapy
  • Immunology
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Tuyishime, M., Garrido, C., Jha, S., Moeser, M., Mielke, D., LaBranche, C., … Ferrari, G. (2020). Improved killing of HIV-infected cells using three neutralizing and non-neutralizing antibodies. J Clin Invest, 130(10), 5157–5170. https://doi.org/10.1172/JCI135557
Tuyishime, Marina, Carolina Garrido, Shalini Jha, Matt Moeser, Dieter Mielke, Celia LaBranche, David Montefiori, et al. “Improved killing of HIV-infected cells using three neutralizing and non-neutralizing antibodies.J Clin Invest 130, no. 10 (October 1, 2020): 5157–70. https://doi.org/10.1172/JCI135557.
Tuyishime M, Garrido C, Jha S, Moeser M, Mielke D, LaBranche C, et al. Improved killing of HIV-infected cells using three neutralizing and non-neutralizing antibodies. J Clin Invest. 2020 Oct 1;130(10):5157–70.
Tuyishime, Marina, et al. “Improved killing of HIV-infected cells using three neutralizing and non-neutralizing antibodies.J Clin Invest, vol. 130, no. 10, Oct. 2020, pp. 5157–70. Pubmed, doi:10.1172/JCI135557.
Tuyishime M, Garrido C, Jha S, Moeser M, Mielke D, LaBranche C, Montefiori D, Haynes BF, Joseph S, Margolis DM, Ferrari G. Improved killing of HIV-infected cells using three neutralizing and non-neutralizing antibodies. J Clin Invest. 2020 Oct 1;130(10):5157–5170.

Published In

J Clin Invest

DOI

EISSN

1558-8238

Publication Date

October 1, 2020

Volume

130

Issue

10

Start / End Page

5157 / 5170

Location

United States

Related Subject Headings

  • Virus Latency
  • Neutralization Tests
  • Middle Aged
  • Male
  • Kinetics
  • Killer Cells, Natural
  • In Vitro Techniques
  • Immunotherapy
  • Immunology
  • Humans